FundedIQ
Biotechnology

Eyenovia: Funding, Investors & Team (Oct 2026)

Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics. Eyenovia was founded in 2014.

hyperiondefi.com LinkedIn New York, United States 11-50 employees
Biotechnology Pharmaceutical B2B
Total raised
$10.0M
Rounds
1
Latest
Undisclosed round
May 2026

Eyenovia has raised $10.0M across 1 funding round on record, the most recent an undisclosed round of $10.0M announced in May 2026.

That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Eyenovia Company Profile and Key Stats

Total funding raised
$10.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$10.0M in May 2026
Employees
11-50
reported band
Headquarters
New York, United States

Latest funding round on record: May 2026.

Eyenovia Funding Rounds

Date
Round
Amount
Undisclosed round
$10.0M

Eyenovia Founders and Leadership Team

Name
Role
Contact
Michael Rowe
Founder
Locked

Contact details for the Eyenovia team: 1 has a LinkedIn profile.

Start 14-day free trial →

Eyenovia Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,185
$8.4M
30,319
$7.7M

Eyenovia's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Eyenovia in Biotechnology and New York

Companies Similar to Eyenovia

Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…

Series B $50.0M

Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…

Series A $37.0M
Series B $150M

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…

Undisclosed round $94.0M

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…

Series B $9.5M

Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…

Series B $33.0M

Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…

Undisclosed round —

Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.

Series A $15.0M

Serán is a contract development and manufacturing organization providing a comprehensive suite of…

Private Equity —

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…

Series D $250M

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…

Series E $311M

Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…

Undisclosed round $8.5M

Eyenovia Funding FAQs

What does Eyenovia do?

Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics. Eyenovia was founded in 2014.

How much funding has Eyenovia raised?

Eyenovia has raised $10.0M across 1 round on record. The most recent is an undisclosed round of $10.0M announced in May 2026.

When did Eyenovia last raise funding?

Eyenovia's most recent funding round on record is an undisclosed round of $10.0M, announced in May 2026.

Who founded Eyenovia?

FundedIQ lists Michael Rowe (Founder) at Eyenovia.

Where is Eyenovia headquartered?

Eyenovia is based in New York, New York, United States.

How many employees does Eyenovia have?

Eyenovia is in the 11-50 employee band.

How does Eyenovia's funding compare to other Biotechnology startups?

Eyenovia's latest round of $10.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.

About FundedIQ's Eyenovia Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eyenovia is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.